Bank of America Corp vs Bristol-Myers Squibb Co — how do they compare? Bank of America Corp trades at $63.96 (market cap $446.56B), while Bristol-Myers Squibb Co trades at $63.74 (market cap $132.45B). The key difference: Bank of America Corp is far larger — about 3.4× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| BAC | BMY | |
|---|---|---|
Market Cap | $446.56B | $132.45B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $64.00 | $65.89 |
52-Week Low | $46.72 | $42.60 |
Dividend Yield | 2% | 3.89% |
Enterprise Value | — | $166.44B |
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $64.00, up 1.31% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals, including a P/E of 14.75 and net income margin of 28.21%, supported by revenue growth to $113.10 billion in 2025. Recent news highlights partnerships, hiring initiatives, and positive analyst coverage, with a consensus price target of $67.36.
Outlook remains positive with potential upside from capital returns and earnings growth, though risks include macroeconomic sensitivity and high RSI levels. Analyst consensus is strongly bullish with 64.82% buy ratings, indicating confidence in BAC's deposit franchise and operational strength amid evolving rate cycles.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →